Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
PENN Interactive adjusted EBITDA loss narrows 84.7% to ($9.5 million) in Q2 2026

PENN Interactive adjusted EBITDA loss narrows 84.7% to ($9.5 million) in Q2 2026

ReutersReuters2026/08/06 11:04
  • Penn Entertainment posted Q2 2026 retail revenue up 3.9% to $1.51 billion; adjusted EBITDAR rose 5.6% to $517.2 million.
  • Interactive adjusted revenue fell 8% to $163.9 million; adjusted EBITDA loss narrowed to $9.5 million from $62 million a year earlier.
  • Average monthly active users dropped 14.4% to 417,000; ARPMAU increased 4% to $104.
  • 2026 guidance midpoint for retail adjusted EBITDAR increased $31 million to $1.96 billion; interactive adjusted EBITDA guidance stayed at a $20 million loss.
  • Management highlighted record quarterly retail revenue, citing strength across the portfolio and contributions from four recently completed development projects.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penn Entertainment Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.